QuidelOrtho (NASDAQ:QDEL) Trading 9.2% Higher – What’s Next?

Posted by George Bondi on Jun 4th, 2026

QuidelOrtho Corporation (NASDAQ:QDEL – Get Free Report)’s share price traded up 9.2% on Thursday . The stock traded as high as $14.72 and last traded at $14.8470. 152,980 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 1,832,095 shares. The stock had previously closed at $13.60.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on QDEL shares. Zacks Research lowered shares of QuidelOrtho from a “hold” rating to a “strong sell” rating in a report on Tuesday, February 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of QuidelOrtho in a report on Tuesday, April 21st. UBS Group reaffirmed a “neutral” rating and set a $12.00 price objective on shares of QuidelOrtho in a report on Thursday, May 7th. Wall Street Zen lowered shares of QuidelOrtho from a “buy” rating to a “hold” rating in a report on Sunday, April 12th. Finally, Jefferies Financial Group downgraded shares of QuidelOrtho from a “buy” rating to a “hold” rating and dropped their price objective for the company from $35.00 to $12.50 in a report on Thursday, May 7th. Three equities research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus target price of $14.88.

Get Our Latest Research Report on QDEL

QuidelOrtho Price Performance

The firm’s fifty day simple moving average is $13.25 and its 200 day simple moving average is $21.65. The firm has a market cap of $1.02 billion, a P/E ratio of -0.84 and a beta of 0.77. The company has a debt-to-equity ratio of 1.33, a quick ratio of 0.80 and a current ratio of 1.43.

QuidelOrtho (NASDAQ:QDEL – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of $0.37 by ($0.41). QuidelOrtho had a negative net margin of 45.57% and a positive return on equity of 4.25%. The company had revenue of $619.80 million for the quarter, compared to the consensus estimate of $665.23 million. During the same period last year, the company earned $0.74 EPS. The firm’s revenue for the quarter was down 10.5% on a year-over-year basis. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. As a group, analysts forecast that QuidelOrtho Corporation will post 1.83 earnings per share for the current year.

Institutional Trading of QuidelOrtho

Hedge funds have recently made changes to their positions in the business. Royal Bank of Canada raised its position in shares of QuidelOrtho by 1,218.7% during the 1st quarter. Royal Bank of Canada now owns 80,193 shares of the company’s stock valued at $2,803,000 after buying an additional 74,112 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of QuidelOrtho by 10.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 228,398 shares of the company’s stock valued at $7,987,000 after buying an additional 21,968 shares in the last quarter. Focus Partners Wealth raised its position in shares of QuidelOrtho by 210.9% during the 1st quarter. Focus Partners Wealth now owns 20,454 shares of the company’s stock valued at $715,000 after buying an additional 13,876 shares in the last quarter. Arrowstreet Capital Limited Partnership purchased a new stake in shares of QuidelOrtho during the 2nd quarter valued at about $1,313,000. Finally, EverSource Wealth Advisors LLC raised its position in shares of QuidelOrtho by 250.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,230 shares of the company’s stock valued at $93,000 after buying an additional 2,309 shares in the last quarter. 99.00% of the stock is currently owned by hedge funds and other institutional investors.

About QuidelOrtho

(Get Free Report)

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.

Receive News & Ratings for QuidelOrtho Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuidelOrtho and related companies with MarketBeat.com's FREE daily email newsletter.